Literature DB >> 19454703

Antiviral antibodies target adenovirus to phagolysosomes and amplify the innate immune response.

Anne K Zaiss1, Akosua Vilaysane, Matthew J Cotter, Sharon A Clark, H Christopher Meijndert, Pina Colarusso, Robin M Yates, Virginie Petrilli, Jurg Tschopp, Daniel A Muruve.   

Abstract

Adenovirus is a nonenveloped dsDNA virus that activates intracellular innate immune pathways. In vivo, adenovirus-immunized mice displayed an enhanced innate immune response and diminished virus-mediated gene delivery following challenge with the adenovirus vector AdLacZ suggesting that antiviral Abs modulate viral interactions with innate immune cells. Under naive serum conditions in vitro, adenovirus binding and internalization in macrophages and the subsequent activation of innate immune mechanisms were inefficient. In contrast to the neutralizing effect observed in nonhematopoietic cells, adenovirus infection in the presence of antiviral Abs significantly increased FcR-dependent viral internalization in macrophages. In direct correlation with the increased viral internalization, antiviral Abs amplified the innate immune response to adenovirus as determined by the expression of NF-kappaB-dependent genes, type I IFNs, and caspase-dependent IL-1beta maturation. Immune serum amplified TLR9-independent type I IFN expression and enhanced NLRP3-dependent IL-1beta maturation in response to adenovirus, confirming that antiviral Abs specifically amplify intracellular innate pathways. In the presence of Abs, confocal microscopy demonstrated increased targeting of adenovirus to LAMP1-positive phagolysosomes in macrophages but not epithelial cells. These data show that antiviral Abs subvert natural viral tropism and target the adenovirus to phagolysosomes and the intracellular innate immune system in macrophages. Furthermore, these results illustrate a cross-talk where the adaptive immune system positively regulates the innate immune system and the antiviral state.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19454703     DOI: 10.4049/jimmunol.0804269

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

Review 1.  Inflammasomes in the CNS.

Authors:  John G Walsh; Daniel A Muruve; Christopher Power
Journal:  Nat Rev Neurosci       Date:  2014-01-08       Impact factor: 34.870

2.  Lysosomal localization and mechanism of membrane penetration influence nonenveloped virus activation of the NLRP3 inflammasome.

Authors:  A U Barlan; P Danthi; C M Wiethoff
Journal:  Virology       Date:  2011-02-18       Impact factor: 3.616

Review 3.  Adenovirus-triggered innate signalling pathways.

Authors:  G Fejer; M Freudenberg; U F Greber; I Gyory
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2011-12-23

Review 4.  Adenoviral vector immunity: its implications and circumvention strategies.

Authors:  Yadvinder S Ahi; Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Gene Ther       Date:  2011-08       Impact factor: 4.391

5.  MyD88-dependent protective immunity elicited by adenovirus 5 expressing the surface antigen 1 from Toxoplasma gondii is mediated by CD8(+) T lymphocytes.

Authors:  Erica A Mendes; Bráulia C Caetano; Marcus L O Penido; Oscar Bruna-Romero; Ricardo T Gazzinelli
Journal:  Vaccine       Date:  2011-05-05       Impact factor: 3.641

6.  Human lung innate immune cytokine response to adenovirus type 7.

Authors:  Wenxin Wu; J Leland Booth; Elizabeth S Duggan; Krupa B Patel; K Mark Coggeshall; Jordan P Metcalf
Journal:  J Gen Virol       Date:  2010-01-13       Impact factor: 3.891

Review 7.  The influence of innate and pre-existing immunity on adenovirus therapy.

Authors:  Anne K Zaiss; Hidevaldo B Machado; Harvey R Herschman
Journal:  J Cell Biochem       Date:  2009-11-01       Impact factor: 4.429

Review 8.  Circumventing antivector immunity: potential use of nonhuman adenoviral vectors.

Authors:  Estrella Lopez-Gordo; Iva I Podgorski; Nicholas Downes; Ramon Alemany
Journal:  Hum Gene Ther       Date:  2014-03-25       Impact factor: 5.695

9.  Diminished Innate Antiviral Response to Adenovirus Vectors in cGAS/STING-Deficient Mice Minimally Impacts Adaptive Immunity.

Authors:  Daniela Anghelina; Eric Lam; Erik Falck-Pedersen
Journal:  J Virol       Date:  2016-06-10       Impact factor: 5.103

Review 10.  Adenovirus vectors for gene therapy, vaccination and cancer gene therapy.

Authors:  William S M Wold; Karoly Toth
Journal:  Curr Gene Ther       Date:  2013-12       Impact factor: 4.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.